Skip to content
Bal Pharma logo

Bal Pharma

BALPHARMA NSE
₹86.89 up 0.72 (0.84%)
Market Cap
₹138 Cr
P/E
19.22

Bal Pharma (BALPHARMA) share price was ₹86.17 at the 28 Oct 2026 close; market capitalisation ₹137 Cr; P/E (TTM) 19.06; sector Healthcare. The share price rose 4.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 34.5% year on year to ₹88.62 Cr and net profit was ₹1.13 Cr, against ₹0.21 Cr a year earlier (compared with Jun 2025). Promoters held 50.86% of Bal Pharma in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 52/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹86.17 +3.22 +3.88% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹138 Cr
P/E (TTM)
19.22
EBITDA
₹33.80 Cr
Return on Equity
7.68%
Debt to Equity
1.95
Book Value
₹51.65
EPS (TTM)
₹4.52
52W High
₹124.60
52W Low
₹60.00

Price-based figures as of 29 Oct 2026, 10:42 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.2035.044,23,771 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,654.0087.622,56,283 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,606.6072.321,75,220 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,186.60108.031,18,145 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.4026.271,17,745 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.8034.671,11,747 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.6032.691,10,240 Cr3.110.96%11.21%14.88%28,589 Cr3,356 Cr
Bal Pharma (this company)
₹86.8919.22138 Cr1.681.45%7.68%18.01%336 Cr7 Cr
Median 8 companies₹1,565.4034.861,17,945 Cr4.710.72%12.98%17.98%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

52 Average
Overall score

Data confidence 100/100

surveillance:ESM1

Category scores

Quality Good 59
Returns, margins, earnings quality 22% weight
Valuation Strong 68
Cheap vs sector & own history 24% weight
Growth Good 57
Sales & profit trajectory 9% weight
Financial Health Poor 21
Solvency, leverage, coverage 9% weight
Momentum Strong 70
Trend strength, vol-adjusted 12% weight
Ownership Average 53
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 27.5%

Weaknesses

4
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 4.46% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 9.37% over last 3 years.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

Bearish

Bearish
11
Neutral
7
Bullish
1

Moving Averages

Bearish

Bearish
9
Neutral
0
Bullish
1

Growth Rate

Revenue Growth
2.72% higher than 3Y

change over 1 year

Net Income Growth
-12.5% lower than 3Y

change over 1 year

Cash Flow Change
51.85%

change over 1 year

EBITDA Margin Change
3.75%

change over 1 year Operating margin 8.97% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
70.39
92.54
81.66
94.63
74.36
73.69
73.15
81.88
65.87
74.02
87.69
84.08
88.62
Expenses
63.95
84.84
73.87
85.03
67.89
66
65.4
74.24
59.81
68.29
78.15
73.5
80.67
Operating Profit
6.44
7.7
7.79
9.6
6.47
7.69
7.75
7.64
6.06
5.73
9.54
10.58
7.95
OPM %
9.15%
8.32%
9.54%
10.14%
8.7%
10.44%
10.59%
9.33%
9.2%
7.74%
10.88%
12.58%
8.97%
Other Income
0.16
0.14
0.1
2.45
0.82
-0.2
0.51
1.08
0.72
1.12
0.33
-0.24
0.44
Interest
3.64
3.82
3.66
4.14
4.24
3.65
5.01
3.95
4.05
3.86
4.85
4.06
4.47
Depreciation
2.53
2.42
2.96
2.16
2.43
2.48
2.69
2.18
2.52
2.27
3.23
3.06
2.78
PBT
0.43
1.6
1.27
5.75
0.62
1.36
0.56
2.59
0.21
0.72
1.79
3.22
1.14
Tax %
79.07%
39.38%
33.07%
3.65%
58.06%
23.53%
7.14%
-108.88%
0%
0%
0%
-12.11%
0%
Net Profit
0.09
0.97
0.85
5.53
0.26
1.04
0.52
5.41
0.21
0.72
1.79
3.6
1.13
EPS (₹)
0.05
0.61
0.56
3.46
0.16
0.65
0.3
3.41
0.13
0.45
1.12
2.25
0.7
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
187
198
229
211
225
171
251
281
304
339
303
312
334
Expenses
170
183
214
194
207
166
226
257
279
308
273
280
301
Operating Profit
17
15
15
17
18
5
25
24
25
31
30
32
34
OPM %
9%
7%
6%
8%
8%
2.9%
10%
9%
8%
9%
10%
10%
10%
Other Income
1
1
3
2
1
2
1
5
1
3
2
2
2
Interest
7
6
8
9
13
13
12
11
12
15
17
17
17
Depreciation
7
7
6
7
6
8
10
9
9
10
10
11
11
PBT
5
3
3
3
0
-14
4
9
5
9
5
6
7
Tax %
25%
90%
114%
87%
-1175%
-5%
-15%
38%
45%
18%
-41%
-7%
—
Net Profit
4
1
0
0
2
-13
5
6
3
7
7
6
7
EPS (₹)
2.82
1.1
1.24
1.96
2.67
-8.62
3.2
3.78
1.64
4.68
4.53
3.94
4.52
Div. Payout %
35%
91%
81%
51%
37%
0%
31%
26%
61%
26%
26%
30%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
14
14
14
14
15
15
16
16
16
16
Reserves
42
42
48
51
52
38
39
44
48
56
62
66
Borrowings
49
89
93
110
124
118
110
104
131
140
150
160
Other Liabilities
59
67
78
86
71
68
76
98
116
108
108
134
Total Liabilities
164
211
233
260
261
238
240
261
311
320
336
376
Fixed Assets
52
56
60
71
70
71
69
67
76
80
87
94
CWIP
1
4
2
0
4
3
0
2
0
0
3
7
Investments
0
0
0
0
0
0
0
0
0
7
2
2
Other Assets
111
151
172
188
187
164
172
192
235
233
244
272
Total Assets
164
211
233
260
261
238
240
261
311
320
336
376
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
15
-19
6
1
8
23
22
27
-2
23
20
30
Investing
-5
-14
-8
-4
-8
-5
-6
-9
-22
-19
-15
-21
Financing
-7
32
-6
4
0
-20
-17
-17
24
-1
-8
-10
Net Cash Flow
2
-1
-8
1
0
-2
0
0
0
3
-2
0
Free Cash Flow
9
-34
-2
-3
-1
18
19
18
-16
12
2
8
CFO/OP
93
-125
52
11
57
465
91
117
-4
88
75
95
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
105
99
111
105
106
98
98
113
107
111
110
Inventory Days
132
145
172
240
217
292
146
162
207
167
238
269
Days Payable
142
163
171
182
147
167
114
143
167
147
189
206
Cash Conversion Cycle
78
87
100
168
175
231
130
117
153
127
161
173
Working Capital Days
14
50
26
45
25
-11
11
18
13
12
6
7
ROCE %
11%
7%
8%
8%
7%
0%
10%
12%
10%
12%
10%
10%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bal Pharma insights

75 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

FIIs0.28%Promot.50.86%Others15.39%Public33.48%As ofSep 2026

Documents

Frequently Asked Questions about Bal Pharma

What does Bal Pharma Ltd do?
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]
Where is Bal Pharma Ltd (BALPHARMA) listed?
Bal Pharma Ltd trades as BALPHARMA on the NSE and under code 524824 on the BSE.
Which sector does Bal Pharma Ltd belong to?
Bal Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bal Pharma Ltd?
Bal Pharma Ltd has a market capitalisation of ₹138.34 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Bal Pharma Ltd?
Bal Pharma Ltd trades at a PE ratio of 19.22 as of 29 Oct 2026, on earnings per share of ₹4.52, against a book value of ₹51.65 per share.
What is the 52-week high and low of Bal Pharma Ltd?
Over the last 52 weeks Bal Pharma Ltd has traded between ₹60 and ₹124.6 as of 29 Oct 2026.
Does Bal Pharma Ltd pay dividends?
Bal Pharma Ltd has a dividend yield of 1.39%.
What is the Return on Equity (ROE) of Bal Pharma Ltd?
Bal Pharma Ltd reported a return on equity of 7.68%. Its debt-to-equity ratio is 1.95.

Company Information

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Website balpharma.com
CEO Mr. Shailesh Dheerajmal Siroya
Employees 986
Listed 2006-05-08
Face Value ₹ 10
Shares Outstanding 1,59,20,872

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BALPHARMA.md for Bal Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month